Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Onco... (expression as determined by both i...)

HOME >> MEDICINE >> TECHNOLOGY

Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)

Date:12/17/2007

expression, as determined by

both immunohistochemistry (IHC) and RT-PCR (as measured by Oncotype

DX), was prognostic in a group of ER-positive and ER-negative patients.

RT-PCR results were more continuously distributed with a large dynamic

range than estrogen receptor expression measured by IHC, which was

generally either very high or very low. Among estrogen receptor-

positive, tamoxifen-treated patients, only quantitative RT-PCR using

Oncotype DX allowed for a risk comparison across levels of estrogen

receptor expression, and identified a 2.5-fold increase in survival for

those with the highest quantitative estrogen receptor expression. Based

on these and other results, Genomic Health plans to provide individual

estrogen and progesterone receptor scores as an enhancement to Oncotype

DX Recurrence Score reports beginning in early 2008.

Other Oncotype DX Studies

* An oral presentation on Saturday, December 15 showed Recurrence Score

results were significantly predictive of recurrence in both node

negative disease and node-positive disease, and demonstrated that

Oncotype DX provides additional prognostic information beyond that

developed by Adjuvant Online.

* A separate study presented on Thursday, December 13 by Istituto

Nazionale dei Tumori in Italy demonstrated that Recurrence Score

results from a primary diagnosis of breast cancer are also associated

with survival in the first two years after recurrence. Specifically,

those with low Recurrence Score results experienced longer survival

after recurrence.

* Finally, a study presented by Genomic Health on Friday, December 14

reported gene expression profiles as measured by Oncotype DX in

histologically characterized breast cancers including ductal, lobular,

or mixed, as wel
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease

Post Your Comments:

Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Onco...(expression as determined by both i...),Health